vs
Side-by-side financial comparison of Ellington Credit Co (EARN) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Ellington Credit Co is the larger business by last-quarter revenue ($6.1M vs $5.5M, roughly 1.1× Taysha Gene Therapies, Inc.). Ellington Credit Co runs the higher net margin — -32.6% vs -507.8%, a 475.1% gap on every dollar of revenue. On growth, Ellington Credit Co posted the faster year-over-year revenue change (1528.9% vs 171.3%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 6.3%).
Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
EARN vs TSHA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $5.5M |
| Net Profit | $-2.0M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | -35.6% | -516.0% |
| Net Margin | -32.6% | -507.8% |
| Revenue YoY | 1528.9% | 171.3% |
| Net Profit YoY | -116.1% | -48.3% |
| EPS (diluted) | — | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $6.1M | $2.0M | ||
| Q3 24 | $4.8M | $1.8M | ||
| Q2 24 | $3.9M | $1.1M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | — | $-27.9M | ||
| Q3 25 | — | $-32.7M | ||
| Q2 25 | — | $-26.9M | ||
| Q1 25 | — | $-21.5M | ||
| Q4 24 | $-2.0M | $-18.8M | ||
| Q3 24 | $5.4M | $-25.5M | ||
| Q2 24 | $-815.0K | $-20.9M | ||
| Q1 24 | — | $-24.1M |
| Q4 25 | — | -516.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1347.1% | ||
| Q1 25 | — | -930.5% | ||
| Q4 24 | -35.6% | -985.8% | ||
| Q3 24 | — | -1448.4% | ||
| Q2 24 | -22.8% | -1915.4% | ||
| Q1 24 | — | -713.3% |
| Q4 25 | — | -507.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1353.6% | ||
| Q1 25 | — | -935.2% | ||
| Q4 24 | -32.6% | -929.0% | ||
| Q3 24 | 114.6% | -1427.5% | ||
| Q2 24 | -20.9% | -1882.0% | ||
| Q1 24 | — | -705.4% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.8M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $193.7M | $246.9M |
| Total Assets | $824.1M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $319.8M | ||
| Q3 25 | — | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | $31.8M | $139.0M | ||
| Q3 24 | $25.7M | $157.7M | ||
| Q2 24 | $118.8M | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | — | $246.9M | ||
| Q3 25 | — | $219.0M | ||
| Q2 25 | — | $248.7M | ||
| Q1 25 | — | $55.1M | ||
| Q4 24 | $193.7M | $71.5M | ||
| Q3 24 | $191.6M | $88.8M | ||
| Q2 24 | $146.1M | $108.9M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | $343.3M | ||
| Q3 25 | — | $316.6M | ||
| Q2 25 | — | $333.3M | ||
| Q1 25 | — | $138.4M | ||
| Q4 24 | $824.1M | $160.4M | ||
| Q3 24 | $752.3M | $180.2M | ||
| Q2 24 | $933.5M | $200.4M | ||
| Q1 24 | — | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-24.2M | ||
| Q2 25 | — | $-20.2M | ||
| Q1 25 | — | $-22.0M | ||
| Q4 24 | $4.4M | $-18.3M | ||
| Q3 24 | $3.2M | $-21.6M | ||
| Q2 24 | $2.7M | $-21.5M | ||
| Q1 24 | — | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
